|Bid||62.00 x 300|
|Ask||63.26 x 100|
|Day's Range||62.15 - 62.76|
|52 Week Range||42.31 - 64.60|
|PE Ratio (TTM)||232.90|
|Forward Dividend & Yield||1.12 (1.77%)|
|1y Target Est||N/A|
- National reimbursement adds the device into Japan's health insurance system, which enables greater access for patients - MitraClip is a first-of-its-kind transcatheter mitral valve repair device that ...
-- HEARTMATE 3™ LVAD DEMONSTRATED IMPROVED CLINICAL OUTCOMES OVER THE MOST WIDELY USED LVAD IN THE WORLD -- MOMENTUM 3 STUDY MET THE PRIMARY ENDPOINT AT TWO YEARS -- RESULTS PRESENTED AT ACC AND SIMULTANEOUSLY ...
ABBOTT PARK, Ill., March 6, 2018 /PRNewswire/ -- Abbott today announced the U.S. Food and Drug Administration (FDA) approved the Masters HP™ 15mm rotatable mechanical heart valve, the world's smallest mechanical heart valve, that will allow doctors to treat babies and toddlers in need of a mitral or aortic valve replacement. Until today, surgeons could only use a range of larger-sized valves to replace a pediatric heart valve that could not be repaired, and larger valves are often not suitable given the smaller size of children's hearts. This dime-sized new valve is the first and only pediatric mechanical heart valve developed for newborns and infants, and offers hope for pediatric patients in urgent need of treatment who have no other approved options.
ABBOTT PARK, Ill., March 1, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will participate in the Barclays Capital Global Healthcare Conference on Wednesday, March 14, 2018 . Brian Yoor , executive vice president, ...
- COMPANIES TO COLLABORATE ON PRODUCT DEVELOPMENT, CLINICAL TRIALS AND REGULATORY ACTIVITIES TO OBTAIN APPROVAL IN U.S. AND E.U. ABBOTT PARK, Ill. and EDEN PRAIRIE, Minn., Feb. 27, 2018 /PRNewswire/ -- Abbott (ABT) and Surmodics (SRDX) today announced that the companies have entered into an agreement whereby Abbott will have exclusive worldwide commercialization rights for Surmodics' SurVeil® drug-coated balloon to treat the superficial femoral artery, which is currently being evaluated in a U.S. pivotal clinical trial.
ABBOTT PARK, Ill., Feb. 16, 2018 /PRNewswire/ -- The board of directors of Abbott (ABT) today declared a quarterly common dividend of 28 cents per share. This marks the 377th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2018, to shareholders of record at the close of business on April 13, 2018.
NEW YORK, NY / ACCESSWIRE / February 15, 2018 / U.S. markets rallied sharply from early losses Wednesday as inflation fears appear to be easing on Wall Street. The Dow Jones Industrial Average jumped 1.03 ...
ABBOTT PARK, Ill., Feb. 7, 2018 /PRNewswire/ -- Abbott (ABT) announced today the FreeStyle LibreLink app is now available in Europe for use with compatible smartphones2 (both iPhone and Android). People with diabetes living in Europe and using the FreeStyle® Libre system3 are now able to access glucose data directly from their smartphones, eliminating the need to carry the separate FreeStyle Libre reader4 (a handheld device used to scan the FreeStyle Libre sensor to get a glucose result). Since 2015 the app offering for the FreeStyle Libre system was only available for Android users but now the FreeStyle LibreLink app is also compatible with iPhone.
NEW YORK, Feb. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alexander's, ...
Stock Monitor: Abbott Laboratories Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 26, 2018 / Active-Investors.com has just released a free earnings report on Accuray Inc. (NASDAQ: ARAY ). If ...
- Fourth-quarter reported sales growth of 42.3 percent; comparable operational sales growth of 7.7 percent - Numerous new product approvals and launches across diverse business portfolio - Issues earnings ...
ABBOTT PARK, Ill., Jan. 4, 2018 /PRNewswire/ -- Abbott (ABT) today announced that the FreeStyle® Libre System, the company's revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients, having met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS). Coverage includes all Medicare patients with diabetes who use insulin and who meet the eligibility criteria2.
NEW MR-CONDITIONAL LABELING FOR TWO OF THE COMPANY'S MOST WIDELY-USED HIGH VOLTAGE DEVICES CONTINUE CADENCE OF MRI APPROVALS WITHIN ABBOTT'S CARDIAC RHYTHM MANAGEMENT PORTFOLIO ABBOTT PARK, Ill., Jan. ...
ABBOTT PARK, Ill., Jan. 2, 2018 /PRNewswire/ -- Abbott (ABT) today announced CE Mark for its Alinity h-series integrated system for hematology testing, joining the Alinity hq standalone hematology analyzer, which obtained CE Mark earlier this year. The new Alinity h-series solution integrates the Alinity hq with the Alinity hs slide maker and stainer module into a combined solution. The Alinity h-series solution is 20 percent faster per m2 than other currently available integrated hematology systems with a throughput of 133 complete blood counts (CBCs) per m2.
ABBOTT PARK, Ill., Dec. 18, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2017 financial results on Wednesday, Jan. 24, 2018 , before the market opens. The announcement will ...
ABBOTT PARK, Ill., Dec. 15, 2017 /PRNewswire/ -- The board of directors of Abbott (ABT) today increased the company's quarterly common dividend to 28 cents per share from 26.5 cents per share. This marks the 376th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Feb. 15, 2018, to shareholders of record at the close of business on Jan. 12, 2018.
ABBOTT PARK, Ill., Dec. 4, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 36 th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 8, 2018 . Brian Yoor , executive vice president of ...
ABBOTT PARK, Ill., Nov. 6, 2017 /PRNewswire/ -- Abbott (ABT) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the company's MitraClip device for treatment of people with mitral regurgitation (MR), a serious, progressive heart disease in which the mitral valve does not close properly, allowing blood to flow backward into the heart. MR causes many life-altering symptoms, and left untreated, can ultimately lead to heart failure and death. "MitraClip provides a new treatment option for many people with severe mitral regurgitation who cannot undergo the mitral valve surgery," said Kentaro Hayashida, M.D., Cardiovascular Internal Medicine, Keio University, Tokyo and principal investigator of the AVJ-514 clinical trial.
ABBOTT PARK, Ill., Oct. 31, 2017 /PRNewswire/ -- Abbott (ABT) has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Alinity™ ci-series instruments for clinical chemistry and immunoassay diagnostics. "Healthcare systems across the United States are under pressure to deliver better care for patients," said Brian Blaser, executive vice president, Diagnostics Products, Abbott. "Labs and healthcare systems are looking for complete solutions that help them operate more efficiently while contributing to better clinical decision making and helping improve patient outcomes.
The data were presented during a late-breaking session at the 29th Transcatheter Cardiovascular Therapeutics (TCT) meeting, the annual scientific symposium of the Cardiovascular Research Foundation. "For any treatment, it's important to not only consider clinical outcomes such as recurrent heart attacks or stroke, but also to consider the effect of the treatment on a patient's quality of life," said Suzanne J. Baron, M.D., study investigator and assistant professor of medicine at the University of Missouri-Kansas City. Patients were asked to report frequency of chest discomfort (angina), difficulty breathing, symptoms of depression and other physical and mental limitations.
- XIENCE Sierra™, the newest generation of drug-eluting XIENCE stent receives CE Mark, representing European approval - New stent design, new delivery system, and unique sizes improve doctors' ability ...
ABBOTT PARK, Ill., Oct. 23, 2017 /PRNewswire/ -- Abbott (ABT) has secured U.S. Food and Drug Administration (FDA) clearance for the Confirm Rx™ Insertable Cardiac Monitor (ICM), the world's first and only smartphone compatible ICM designed to help physicians remotely identify cardiac arrhythmias. With FDA clearance Abbott can now provide U.S. patients a new way to monitor for abnormal heart rhythms while staying connected to their physician remotely and being able to engage in their health care.
LONDON, UK / ACCESSWIRE / October 20, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Abbott Laboratories (NYSE: ABT ), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=ABT ...
For the 14th year, the journal Science today recognized Abbott on its Top Employers list, which is based on an evaluation of 23 characteristics including financial strength, easy adaptation to change, and a research-driven environment. At Abbott, scientists develop life-changing technologies that help people live their best lives through good health. From freeing people with diabetes from routine finger sticks1, to building a cardiac device to save lives, to hunting for new virus mutations, every day Abbott employees are doing work that matters.